Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. doi: 10.3322/caac.21166
   PubMed Web of Science ®Google Scholar
• George DJ, Sartor O, Miller K, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18(4):284–294. doi: 10.1016/j.clgc.2019.12.019
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis. 2021;16(1):223–249. doi: 10.1146/annurev-pathol-042020-042741
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385(8):683–694. doi: 10.1056/NEJMoa2106391
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi: 10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021;384(9):829–841. doi: 10.1056/NEJMoa2026982
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384(14):1289–1300. doi: 10.1056/NEJMoa2035716
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi: 10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1103–1115. doi: 10.1056/NEJMoa1816047
   PubMed Web of Science ®Google Scholar
• Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. doi: 10.1056/NEJMoa2002788
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102–2114. doi: 10.1056/NEJMoa2034442
   PubMed Web of Science ®Google Scholar
• Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:931–945. doi: 10.1016/S1470-2045(21)00152-2
   PubMed Web of Science ®Google Scholar
• Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in Previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41:22–31. doi: 10.1200/JCO.22.01643
   PubMed Web of Science ®Google Scholar
• Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines insights: prostate cancer, version 1.2021. J Natl Compr Cancer Netw. 2021;19:134–143. doi: 10.6004/jnccn.2021.0008
   PubMed Web of Science ®Google Scholar
• Virgo KS, Basch E, Loblaw DA, et al. Second-line hormonal therapy for men with chemotherapy-naïve, castration-resistant prostate cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2017;35:1952–1964. doi: 10.1200/JCO.2017.72.8030
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi: 10.1056/NEJMoa1014618
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. doi: 10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Subudhi SK, Pieczonka CM, et al. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clin Cancer Res. 2023;29:2426–2434. doi: 10.1158/1078-0432.CCR-22-3832
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–245. doi: 10.1200/JCO.2007.12.4008
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154. doi: 10.1016/S0140-6736(10)61389-X
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223. doi: 10.1056/NEJMoa1213755
   PubMed Web of Science ®Google Scholar
• Garje R, Rumble RB, Parikh RA. Systemic therapy update on 177 lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO Rapid Recommendation. J Clin Oncol. 2022;40:3664–3666. doi: 10.1200/JCO.22.01865
   PubMedGoogle Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091–1103. doi: 10.1056/NEJMoa2107322
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10. doi: 10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden–high solid tumors. Clin Cancer Res. 2021;27:4685–4689. doi: 10.1158/1078-0432.CCR-21-0327
   PubMed Web of Science ®Google Scholar
• Zhang X, Schwartz J-C, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity. 2004;20(3):337–347. doi: 10.1016/S1074-7613(04)00051-2
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):e1792–e1792. doi: 10.1038/cddis.2015.162
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi: 10.1038/nri3862
   PubMed Web of Science ®Google Scholar
• McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37(1):457–495. doi: 10.1146/annurev-immunol-041015-055318
   PubMed Web of Science ®Google Scholar
• Dolina JS, Van Braeckel-Budimir N, Thomas GD, et al. CD8+ T cell exhaustion in cancer. Front Immunol. 2021;12:12. doi: 10.3389/fimmu.2021.715234
   Google Scholar
• Budimir N, Thomas GD, Dolina JS, et al. Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol Res. 2022;10(2):146–153. doi: 10.1158/2326-6066.CIR-21-0515
   PubMed Web of Science ®Google Scholar
• Nimmagadda S. Quantifying PD-L1 expression to monitor immune checkpoint therapy: opportunities and challenges. Cancers (Basel). 2020;12(11):3173. doi: 10.3390/cancers12113173
   PubMed Web of Science ®Google Scholar
• Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278. doi: 10.1186/s40425-019-0768-9
   PubMed Web of Science ®Google Scholar
• Li Y, Huang Q, Zhou Y, et al. The clinicopathologic and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with prostate cancer: a systematic review and meta-analysis. Front Pharmacol. 2019;9:1494. doi: 10.3389/fphar.2018.01494
   PubMed Web of Science ®Google Scholar
• Thoma C. PD-L1 expression is common and indicates poor prognosis. Nat Rev Urol. 2016;13(1):5–5. doi: 10.1038/nrurol.2015.287
   PubMedGoogle Scholar
• Gevensleben H, Dietrich D, Golletz C, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res. 2016;22:1969–1977. doi: 10.1158/1078-0432.CCR-15-2042
   PubMed Web of Science ®Google Scholar
• Ness N, Andersen S, Khanehkenari MR, et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget. 2017;8(16):26789–26801. doi: 10.18632/oncotarget.15817
   PubMedGoogle Scholar
• Petitprez F, Fossati N, Vano Y, et al. PD-L1 expression and CD8+ T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur Urol Focus. 2019;5(2):192–196. doi: 10.1016/j.euf.2017.05.013
   PubMedGoogle Scholar
• Palicelli A, Bonacini M, Croci S, et al. What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 1: focus on immunohistochemical results with discussion of pre-analytical and interpretation variables. Cells. 2021;10(11):3166. doi: 10.3390/cells10113166
   PubMed Web of Science ®Google Scholar
• Haffner MC, Guner G, Taheri D, et al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol. 2018;188:1478–1485. doi: 10.1016/j.ajpath.2018.02.014
   PubMed Web of Science ®Google Scholar
• Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29(8):1807–1813. doi: 10.1093/annonc/mdy232
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395–405. doi: 10.1200/JCO.19.01638
   PubMed Web of Science ®Google Scholar
• Boudadi K, Suzman DL, Anagnostou V, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 2018;9(47):28561–28571. doi: 10.18632/oncotarget.25564
   PubMedGoogle Scholar
• Yu EY, Piulats JM, Gravis G, et al. Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort a study. Eur Urol. 2023;83(1):15–26. doi: 10.1016/j.eururo.2022.08.005
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23:3711–3720. doi: 10.1158/1078-0432.CCR-16-3215
   PubMed Web of Science ®Google Scholar
• Shen J, Zhao W, Ju Z, et al. Parpi triggers the STING-Dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade Independent of BRCAness. Cancer Res. 2019;79(2):311–319. doi: 10.1158/0008-5472.CAN-18-1003
   PubMed Web of Science ®Google Scholar
• Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094–1108. doi: 10.1016/S1470-2045(23)00382-0
   PubMed Web of Science ®Google Scholar
• Graff JN, Liang LW, Kim J, et al. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Futur Oncol. 2021;17:3017–3026. doi: 10.2217/fon-2020-1008
   PubMed Web of Science ®Google Scholar
• Graff JN, Burotto M, Fong PC, et al. 1771MO pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): randomized double-blind phase III KEYNOTE-641 study. Ann Oncol. 2023;34:S957. doi: 10.1016/j.annonc.2023.09.2721
   Google Scholar
• Ardiani A, Farsaci B, Rogers CJ, et al. Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model. Clin Cancer Res. 2013;19:6205–6218. doi: 10.1158/1078-0432.CCR-13-1026
   PubMed Web of Science ®Google Scholar
• Bishop JL, Sio A, Angeles A, et al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget. 2015;6(1):234–242. doi: 10.18632/oncotarget.2703
   PubMed Web of Science ®Google Scholar
• Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016;7(33):52810–52817. doi: 10.18632/oncotarget.10547
   PubMed Web of Science ®Google Scholar
• Tucker MD, Zhu J, Marin D, et al. Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer. Cancer Med. 2019;8:4644–4655. doi: 10.1002/cam4.2375
   PubMed Web of Science ®Google Scholar
• Powles T, Yuen KC, Gillessen S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28(1):144–153. doi: 10.1038/s41591-021-01600-6
   PubMed Web of Science ®Google Scholar
• Gratzke C, Kwiatkowski M, De Giorgi U, et al. KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer. Futur Oncol. 2022;18:4079–4087. doi: 10.2217/fon-2022-0776
   Web of Science ®Google Scholar
• Gratzke CJ, Ozguroglu M, Peer A, et al. 1772MO pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): randomized double-blind phase III KEYNOTE-991 study. Ann Oncol. 2023;34:S957–S958. doi: 10.1016/j.annonc.2023.09.2722
   Web of Science ®Google Scholar
• Petrylak DP, Ratta R, Gafanov R, et al. KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Futur Oncol. 2021;17:3291–3299. doi: 10.2217/fon-2020-1133
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Ratta R, Matsubara N, et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): randomized, double-blind, phase 3 KEYNOTE-921 study. J Clin Oncol. 2023;41(6_suppl):19. doi: 10.1200/JCO.2023.41.6_suppl.19
   Google Scholar
• Fizazi K, González Mella P, Castellano D, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2022;160:61–71. doi: 10.1016/j.ejca.2021.09.043
   PubMed Web of Science ®Google Scholar
• Agarwal N, McGregor B, Maughan BL, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022;23:899–909. doi: 10.1016/S1470-2045(22)00278-9
   PubMed Web of Science ®Google Scholar
• Romano E, Sridhar SS, Kolinsky MP, et al. 620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update. Ann Oncol. 2020;31:S512–S513. doi: 10.1016/j.annonc.2020.08.879
   Web of Science ®Google Scholar
• Antonarakis ES, Park SH, Goh JC, et al. Pembrolizumab plus olaparib for patients with Previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial. J Clin Oncol. 2023;41(22):3839–3850. doi: 10.1200/JCO.23.00233
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091–2102. doi: 10.1056/NEJMoa1911440
   PubMed Web of Science ®Google Scholar
• Fizazi K, Drake CG, Beer TM, et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol. 2020;78(6):822–830. doi: 10.1016/j.eururo.2020.07.032
   PubMed Web of Science ®Google Scholar
• Sharma P, Pachynski RK, Narayan V, et al. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020;38(4):489–499.e3. doi: 10.1016/j.ccell.2020.08.007
   PubMed Web of Science ®Google Scholar
• Sharma P, Krainer M, Saad F, et al. Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): additional results from the randomized phase 2 CheckMate 650 trial. J Clin Oncol. 2023;41:22–22. doi: 10.1200/JCO.2023.41.6_suppl.22
   PubMedGoogle Scholar
• Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–453. doi: 10.1056/NEJMoa1603144
   PubMed Web of Science ®Google Scholar
• Sena LA, Fountain J, Isaacsson Velho P, et al. Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. Oncology. 2021;26(2):e270–e278. Internet. doi: 10.1002/onco.13601
   Google Scholar
• Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471. doi: 10.1001/jamaoncol.2018.5801
   PubMed Web of Science ®Google Scholar
• Graham LS, Montgomery B, Cheng HH, et al. Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies. In: Saleem M, editor. PLoS One. 2020, Vol. 15. p. e0233260. doi: 10.1371/journal.pone.0233260
   Google Scholar
• Lenis AT, Ravichandran V, Truong H, et al. MP24-01 response to immune checkpoint blockade in patients with microsatellite instable and high tumor mutational burden prostate cancer. Urol. 2021;206(Supplement 3):206. doi: 10.1097/JU.0000000000002015.01
   Google Scholar
• Marshall CH, Antonarakis ES. Therapeutic targeting of the DNA damage response in prostate cancer. Curr Opin Oncol. 2020;32:216–222. doi: 10.1097/CCO.0000000000000617
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Phimister EG. Cyclin-dependent kinase 12, immunity, and prostate cancer. Phimister EG, editor. N Engl J Med. 2018;379(11):1087–1089. doi: 10.1056/NEJMcibr1808772
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Isaacsson Velho P, Fu W, et al. CDK12 -altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis Oncol. 2020;370–381. doi: 10.1200/PO.19.00399
   PubMed Web of Science ®Google Scholar
• Antonarakis ES. A new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncology. 2019;24:430–432. doi: 10.1634/theoncologist.2018-0819
   Google Scholar
• Mendes AA, Lu J, Kaur HB, et al. Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer. 2022;128(12):2269–2280. doi: 10.1002/cncr.34190
   PubMed Web of Science ®Google Scholar
• Shi X, Day A, Bergom HE, et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. NPJ Precis Oncol. 2022;6(1):80. doi: 10.1038/s41698-022-00323-2
   PubMed Web of Science ®Google Scholar
• Shenderov E, De Marzo AM, Lotan TL, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med. 2023;29(4):888–897. doi: 10.1038/s41591-023-02284-w
   PubMedGoogle Scholar
• Lanka SM, Zorko NA, Antonarakis ES, et al. Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and beyond. Curr Oncol. 2023;30:4246–4256. doi: 10.3390/curroncol30040323
   PubMed Web of Science ®Google Scholar
• Martin AM, Nirschl TR, Nirschl CJ, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18(4):325–332. doi: 10.1038/pcan.2015.39
   PubMed Web of Science ®Google Scholar
• Wu Z, Chen H, Luo W, et al. The landscape of immune cells infiltrating in prostate cancer. Front Oncol. 2020;10:517637. doi: 10.3389/fonc.2020.517637
   PubMed Web of Science ®Google Scholar
• Andersen LB, Nørgaard M, Rasmussen M, et al. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol. 2021;255(2):155–165. doi: 10.1002/path.5757
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi: 10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• Wang I, Song L, Wang BY, et al. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol. 2022;10(4):210–233.
   PubMed Web of Science ®Google Scholar
• Yi M, Niu M, Xu L, et al. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10. doi: 10.1186/s13045-020-01027-5
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22. doi: 10.1016/j.ccr.2010.05.026
   PubMed Web of Science ®Google Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015:161. doi: 10.1016/j.cell.2015.05.001
   Web of Science ®Google Scholar
• Grasso CS, Wu Y-M, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239–243. doi: 10.1038/nature11125
   PubMed Web of Science ®Google Scholar
• Kumar A, White TA, MacKenzie AP, et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci. 2011;108:17087–17092. doi: 10.1073/pnas.1108745108
   PubMed Web of Science ®Google Scholar
• Wu J, Lin G, Zhu Y, et al. Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status. Sci Rep. 2017;7(1):8869. doi: 10.1038/s41598-017-09484-8
   PubMedGoogle Scholar
• Norström MM, Rådestad E, Sundberg B, et al. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. Oncotarget. 2016;7(17):23581–23593. doi: 10.18632/oncotarget.8051
   PubMedGoogle Scholar
• Zhang X, Chen H, Li G, et al. Increased tim-3 expression on TILs during treatment with the anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer. J Cancer. 2020;11(3):648–656. doi: 10.7150/jca.29705
   PubMed Web of Science ®Google Scholar
• Japp AS, Kursunel MA, Meier S, et al. Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and tim-3 expression. Cancer Immunol Immunother. 2015;64(11):1487–1494. doi: 10.1007/s00262-015-1752-y
   PubMed Web of Science ®Google Scholar
• Jochems C, Tucker JA, Tsang K-Y, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother. 2014;63(4):407–418. doi: 10.1007/s00262-014-1524-0
   PubMed Web of Science ®Google Scholar
• Gao J, Ward JF, Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551–555. doi: 10.1038/nm.4308
   PubMed Web of Science ®Google Scholar
• Cai L, Li Y, Tan J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101. doi: 10.1186/s13045-023-01499-1
   PubMed Web of Science ®Google Scholar
• Shenderov E, Antonarakis ES. B7-H3 and prostate cancer: new therapeutic dance partners. Eur Urol. 2023;83(3):239–240. doi: 10.1016/j.eururo.2022.10.019
   PubMed Web of Science ®Google Scholar
• Han C, Deng Y, Xu W, et al. The roles of tumor-associated macrophages in prostate cancer. In: Khan E, editor. J Oncol. 2022, Vol. 2022. p. 1–20. doi: 10.1155/2022/8580043
   Google Scholar
• Messex JK, Liou G-Y. Impact of Immune Cells in the tumor microenvironment of prostate cancer metastasis. Life. 2023;13(2):333. doi: 10.3390/life13020333
   PubMedGoogle Scholar
• Aggarwal R, Starzinski S, de Kouchkovsky I, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023;24:1266–1276. doi: 10.1016/S1470-2045(23)00451-5
   PubMed Web of Science ®Google Scholar